-
t(11;14) status is stable between diagnosis and relapse, and concordant between detection methodologies based on fluorescence in situ hybridization and next-generation sequencing in patients with multiple myeloma. Haematologica (IF 10.1) Pub Date : 2023-11-23 Hervé Avet-Loiseau, Raphaële Thiébaut-Millot, Xiaotong Li, Jeremy A Ross, Carlos Hader
Multiple myeloma (MM) is associated with a wide variety of recurrent genomic alterations. The most common translocation in MM is t(11;14). In this retrospective, single-center, non-interventional study, patient bone marrow samples were examined at diagnosis and at relapse(s) following treatment with anti-myeloma regimens to determine whether t(11;14) status was stable over time. This Stability Cohort
-
Massive parallel sequencing unveils homologous recombination deficiency in follicular dendritic cell sarcoma. Haematologica (IF 10.1) Pub Date : 2023-11-23 Luisa Lorenzi, Torsten Haferlach, Luigi Mori, Matteo Simbeni, Wencke Walter, Piera Balzarini, Manja Meggendorfer, Claudia Döring, Silvia Lonardi, Mattia Bugatti, Claudio Agostinelli, Jay Mehta, Anita Borges, Abbas Agaimy, Ingrid Simonitsch-Klupp, José Cabeçadas, Elias Campo, Stefano Aldo Pileri, Fabio Facchetti, Martin Leo Hansmann, Sylvia Hartmann
Standardized treatment options are lacking for patients with unresectable or multifocal follicular dendritic cell sarcoma (FDCS) and disease-related mortality is as high as 20%. Applying whole genome sequencing (WGS) in one case and whole exome sequencing (WES) in additional twelve, this study adds information on the molecular landscape of FDCS, expanding knowledge on pathobiological mechanisms and
-
CD38 expression by plasma cells In extramedullary multiple myeloma. Haematologica (IF 10.1) Pub Date : 2023-11-09 Laura Notarfranchi, Fabrizio Accardi, Cristina Mancini, Eugenia Martella, Sabrina Bonomini, Roberta Segreto, Rosanna Vescovini, Anna Benedetta Dalla Palma, Gabriella Sammarelli, Giannalisa Todaro, Paola Storti, Jessica Burroughs-Garcia, Nicolas Thomas Iannozzi, Vincenzo Raimondi, Oxana Lungu, Stefania Ricci, Luisa Craviotto, Nicola Giuliani
Not available.
-
Extended exposure to low doses of azacitidine induces differentiation of leukemic stem cells through activation of myeloperoxidase. Haematologica (IF 10.1) Pub Date : 2023-11-09 Danny V Jeyaraju, Maryam Alapa, Ann Polonskaia, Alberto Risueño, Prakash Subramanyam, Amit Anand, Kaushik Ghosh, Charalampos Kyriakopoulos, Daiane Hemerich, Rose Hurren, Xiaoming Wang, Marcela Gronda, Aarif Ahsan, Hsiling Chiu, Geethu Thomas, Evan F Lind, Daniel L Menezes, Aaron D Schimmer, Patrick R Hagner, Anita Gandhi, Anjan G Thakurta
Oral azacitidine (Oral-Aza; CC-486) treatment results in longer median overall survival (OS) (24.7 vs 14.8 months in placebo) in patients with acute myeloid leukemia (AML) in remission after intensive chemotherapy. The dosing schedule of Oral-Aza (14 days/28-day cycle) allows for low exposure of azacitidine for an extended duration thereby facilitating a sustained therapeutic effect. However, the underlying
-
Autologous-allogeneic versus autologous tandem stem cell transplantation and maintenance therapy with thalidomide for multiple myeloma patients over 60 years of age: a prospective phase II study. Haematologica (IF 10.1) Pub Date : 2023-11-09 Nicolaus Kröger, Gerald Wulf, Ute Hegenbart, Andreas Burchert, Matthias Stelljes, Nico Gagelmann, Arne Brecht, Martin Kaufmann, Lutz Müller, Arnold Ganser, Dominik Wolf, Wolfgang Bethge, Martin Bornhäuser, Michael Kiehl, Eva-Maria Wagner, Christoph Schmid, Hans Christian Reinhardt, Guido Kobbe, Hans Salwender, Thomas Heinicke, Martin Kropff, Marion Heinzelmann, Francis Ayuk, Lorenz Trümper, Andreas
The role of autologous-allogeneic tandem stem cell transplantation (alloTSCT) followed by maintenance as upfront treatment for multiple myeloma (MM) is controversial. Between 2008 and 2014 a total of 217 MM patients with a median age of 51 years were included by 20 German centers within an open-label, parallel-group, multi-center clinical trial to compare alloTSCT to auto tandem transplantation TSCT
-
Impaired hemoglobin clearance by sinusoidal endothelium promotes vaso-occlusion and liver injury in sickle cell disease. Haematologica (IF 10.1) Pub Date : 2023-11-09 Tomasz W Kaminski, Omika Katoch, Ziming Li, Corrine B Hanway, Rikesh K Dubey, Adekunle Alagbe, Tomasz Brzoska, Hong Zhang, Prithu Sundd, Gregory J Kato, Enrico M Novelli, Tirthadipa Pradhan-Sundd
Sickle cell disease (SCD) is a monogenic disorder that affects 100,000 African Americans and millions of people worldwide. Intra-erythrocytic polymerization of sickle hemoglobin (HbS) promotes erythrocyte sickling, impaired rheology, ischemia and hemolysis, leading to the development of progressive liver injury in SCD. Liver resident macrophages and monocytes are known to enable the clearance of HbS
-
Targeting hyperactive platelet-derived growth factor receptor-β signaling in T-cell acute lymphoblastic leukemia and lymphoma. Haematologica (IF 10.1) Pub Date : 2023-11-09 Stien De Coninck, Renate De Smedt, Beatrice Lintermans, Lindy Reunes, Hansen J Kosasih, Alexandra Reekmans, Lauren M Brown, Nadine Van Roy, Bruno Palhais, Juliette Roels, Malaika Van der Linden, Jo Van Dorpe, Panagiotis Ntziachristos, Frederik W Van Delft, Marc R Mansour, Tim Pieters, Tim Lammens, Barbara De Moerloose, Charles E De Bock, Steven Goossens, Pieter Van Vlierberghe
T cell acute lymphoblastic leukemia (T-ALL) and T cell lymphoblastic lymphoma (T-LBL) are rare aggressive hematological malignancies. Current treatment consists of intensive chemotherapy, leading to 80% overall survival but are associated with severe toxic side effects. Furthermore, 10-20% of patients still die from relapsed or refractory disease providing a strong rationale for more specific, targeted
-
Low-dose azacitidine, pioglitazone and all-trans retinoic acid is safe in patients aged ≥ 60 years with acute myeloid leukemia refractory to standard induction chemotherapy (AMLSG 26-16/AML-ViVA): results of the safety run-in phase. Haematologica (IF 10.1) Pub Date : 2023-10-26 Daniel Heudobler,Florian Luke,Joachim Hahn,Matthias Grube,Pavla Schlosser,Stephan Kremers,Thomas Sudhoff,Jorg Westermann,Marie Luise Hutter-Kronke,Richard F Schlenk,Daniela Weber,Peter Paschka,Florian Zeman,Hartmut Dohner,Wolfgang Herr,Albrecht Reichle,Simone Thomas
Not available.
-
Cerebral venous sinus thrombosis and thrombocytopenia due to heparin-independent anti-PF4 antibodies after adenovirus infection. Haematologica (IF 10.1) Pub Date : 2023-10-26 Günalp Uzun,Jan Zlamal,Karina Althaus,Andrea Bevot,Florian Hennersdorf,Nina Wolska,Anna Jock,Jan Kern,Vanya Icheva,Sven Poli,Ulrike Ernemann,Andreas Neu,Tamam Bakchoul
Not available.
-
How we manage a high D-dimer. Haematologica (IF 10.1) Pub Date : 2023-10-26 Massimo Franchini,Daniele Focosi,Mario Piergiulio Pezzo,Pier Mannuccio Mannucci
D-dimer, a soluble fibrin degradation product that originates from plasmin-induced degradation of cross-linked fibrin, is an important biomarker of coagulation activation and secondary fibrinolysis that is routinely used to rule out venous thromboembolism (VTE), to evaluate the risk of VTE recurrence as well as the optimal duration of anticoagulant therapy. Besides VTE, D-dimer may be high due to physiologic
-
A Japanese retrospective study of non-tuberculous mycobacterial infection in children, adolescents, and young adult patients with hematologic-oncologic diseases. Haematologica (IF 10.1) Pub Date : 2023-10-26 Yusuke Tsumura,Hideki Muramatsu,Nobuyuki Tetsuka,Takahiro Imaizumi,Kikue Sato,Kento Inoue,Yoshitomo Motomura,Yuko Cho,Daiki Yamashita,Daichi Sajiki,Ryo Maemura,Ayako Yamamori,Masayuki Imaya,Manabu Wakamatsu,Kotaro Narita,Shinsuke Kataoka,Motoharu Hamada,Rieko Taniguchi,Eri Nishikawa,Atsushi Narita,Nobuhiro Nishio,Seiji Kojima,Yoshihiko Hoshino,Yoshiyuki Takahashi
Non-tuberculous mycobacterial infection (NTM) is rare in healthy children, with lymphadenitis being the most common presentation. Immunocompromised populations are known to be at high risk, but the clinical picture of NTM infection in pediatric hematology/oncology patients is unclear. In this nationwide retrospective analysis of patients under the age of 40 treated in Japanese pediatric hematology/oncology
-
Impact of race and ethnicity on early mortality in multiple myeloma: a SEER analysis. Haematologica (IF 10.1) Pub Date : 2023-10-26 John X Wei,Aditi Shastri,R Alejandro Sica,Ioannis Mantzaris,Noah Kornblum,Urvi Shah,Murali Janakiram,Kira Gritsman,Amit Verma,Mendel Goldfinger,Dennis Cooper,Nishi Shah
Over the past two decades, there have been significant advances in the treatment of multiple myeloma which has led to an improvement in overall survival (OS) (1,2). However, a notable proportion of patients continue to experience early mortality (EM), defined as two years from the time of diagnosis. This raises the possibility that improvements in myeloma survival have not extended equally to all groups
-
Factor VIII genotype and the risk of developing high-responding or low-responding inhibitors in severe hemophilia A: data from the PedNet Hemophilia Cohort of 1,202 children. Haematologica (IF 10.1) Pub Date : 2023-10-26 Nadine G Andersson,Veerle Labarque,Mutlu Kartal-Kaess,Fernando Pinto,Torben Stamm Mikkelsen,Rolf Ljung,PedNet Study Group
Not available.
-
Genome-wide assessment of genetic risk loci for childhood acute lymphoblastic leukemia in Japanese patients. Haematologica (IF 10.1) Pub Date : 2023-10-26 Mayumi Hangai, Takahisa Kawaguchi, Masatoshi Takagi, Keitaro Matsuo, Soyoung Jeon, Charleston W K Chiang, Andrew T Dewan, Adam J De Smith, Toshihiko Imamura, Yasuhiro Okamoto, Akiko M Saito, Takao Deguchi, Michiaki Kubo, Yoichi Tanaka, Yoko Ayukawa, Toshinari Hori, Kentaro Ohki, Nobutaka Kiyokawa, Takeshi Inukai, Yuki Arakawa, Makiko Mori, Daisuke Hasegawa, Daisuke Tomizawa, Hiroko Fukushima, Yuki
Not available.
-
Multiplex immunohistochemistry elucidates increased distance between cytotoxic T cells and plasma cells in relapsed myeloma, and identifies Lag-3 as the most common checkpoint receptor on cytotoxic T cells of myeloma patients. Haematologica (IF 10.1) Pub Date : 2023-10-19 Slavisa Ninkovic, Louise E Purton, Simon J Harrison, Hang Quach
A dysfunctional immune tumour microenvironment facilitates disease progression in multiple myeloma (MM). Using multiplex immunohistochemistry (mIHC), we described the quantitative and qualitative changes in CD3+ CD8+ cytotoxic T-cells and assess their proximity to malignant plasma cells (PCs) in patients with monoclonal gammopathy of undetermined significance (MGUS), newly diagnosed (ND) and relapsed/refractory
-
Impact of mild thrombocytopenia on bleeding and recurrent thrombosis in cancer. Haematologica (IF 10.1) Pub Date : 2023-10-19 Rushad Patell, Charles Hsu, Minggao Shi, Michael A Grosso, Anil Duggal, Harry R Buller, Gary Raskob, Jeffrey I Zwicker
Thrombocytopenia occurs frequently in patients with cancer-associated thrombosis (CAT), however prospective evaluation of clinical outcomes following randomization to anticoagulants is limited. The HOKUSAI VTE Cancer study was a randomized, open-label, non-inferiority, phase III trial comparing dalteparin with edoxaban in CAT patients. This post hoc analysis of Hokusai VTE Cancer Study was performed
-
Glofitamab monotherapy induces high complete response rates and manageable safety in Chinese patients with heavily pretreated relapsed or refractory diffuse large B-cell lymphoma. Haematologica (IF 10.1) Pub Date : 2023-10-19 Yu-Qin Song, Hui-Lai Zhang, Hui-Qiang Huang, Qing-Yuan Zhang, Hong-Mei Jing, Chao Wang, Chun Wu, Dong-Hang Li, Yu Dai, Kathryn Humphrey, Jun Zhu
Not available.
-
Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma: U.S. Myeloma Immunotherapy Consortium real world experience. Haematologica (IF 10.1) Pub Date : 2023-10-19 Hamza Hashmi, Doris K Hansen, Lauren C Peres, Omar Castaneda Puglianini, Ciara Freeman, Gabriel De Avila, Surbhi Sidana, Leyla Shune, Douglas W Sborov, James Davis, Charlotte Wagner, Mehmet H Kocoglu, Shebli Atrash, Peter Voorhees, Gary Simmons, Christopher Ferreri, Nilesh Kalariya, Larry D Anderson, Aimaz Afrough, Danai Dima, Jack Khouri, Joseph McGuirk, Fred Locke, Rachid Baz, Krina K Patel, Melissa
While response rates and survival outcomes have been very promising for idecabtagene vicleucel (ide-cel), a proportion of patients do not respond or relapse early after this B-cell maturation antigen (BCMA) targeted CAR T-cell therapy. Understanding the characteristics of these patients is important for patient selection and development of novel strategies to improve outcomes. We evaluated factors
-
A study of 28 pregnant women with sickle cell disease and COVID-19: elevated maternal and fetal morbidity rates. Haematologica (IF 10.1) Pub Date : 2023-10-19 Laure Joseph, Gonzalo De Luna, Emmanuelle Bernit, Pierre Cougoul, Aline Santin, Benoit Faucher, Anoosha Habibi, Alain Garou, Gylna Loko, Sarah Mattioni, Sandra Manceau, Jean Benoit Arlet, François Lionnet
Not available.
-
Outcomes of limited stage primary bone diffuse large B-cell lymphoma in the rituximab era: a multicenter, retrospective study. Haematologica (IF 10.1) Pub Date : 2023-10-19 Alexandra Rezazadeh, Aniko Szabo, Arushi Khurana, David J Inwards, Matthew A Lunning, Nancy L Bartlett, Paolo F Caimi, Thomas D Rodgers, Paul M Barr, Sayan Mullick Chowdhury, Narendranath Epperla, Hiruni Mendries, Brian T Hill, Timothy S Oh, Reem Karmali, Julie E Chang, Gaurav Goyal, Benjamin M Parsons, Krista M Isaac, Craig A Portell, Kathleen Monahan, Malika Siker, David M King, Timothy S Fenske
Primary bone diffuse large B cell lymphoma (DLBCL) is a rare variant of extranodal non-Hodgkin lymphoma (NHL) historically treated with induction chemotherapy followed by consolidative radiation therapy (RT). It remains unknown whether RT confers additional benefit following rituximab-based chemoimmunotherapy (CIT) induction in patients with limited-stage disease. We conducted a multicenter retrospective
-
Subcutaneous injection of IHP-102 prevents lung vaso-occlusion in sickle cell disease mice. Haematologica (IF 10.1) Pub Date : 2023-10-19 Rikesh K Dubey, Ravi Vats, Tomasz Brzoska, Tomasz W Kaminski, Omika Katoch, Jesus Tejero, Gabriel Njikang, John Paderi, Prithu Sundd
Not available.
-
Talquetamab in multiple myeloma. Haematologica (IF 10.1) Pub Date : 2023-10-19 Lawrence Liu, Amrita Krishnan
Initial results of the Phase 1 trial of talquetamab, a bispecific antibody targeting GPRC5D and CD3, were reported in December of 2022 for the treatment of relapsed or refractory multiple myeloma in the fourth line or later setting. It demonstrated a similar efficacy profile and durability of response to teclistamab, the first bispecific antibody therapy to be approved in multiple myeloma. Additionally
-
Differential transcriptional control of hematopoiesis in congenital and cycling neutropenia patients harboring ELANE mutations. Haematologica (IF 10.1) Pub Date : 2023-10-19 Alexander Zeidler, Natalia Borbaran-Bravo, Benjamin Dannenmann, Malte Ritter, Masoud Nasri, Maksim Klimiankou, Sergey Kandabarau, Azadeh Zahabi, Josef König, Cornelia Zeidler, Julia Skokowa, Karl Welte
Mutations in the ELANE gene, encoding the neutrophil elastase (NE) protein, are responsible for most CyN cases and approximately 25 % of CN cases. In CN and in CyN, a median of 2.8 % of CD34+ cells were early CD49f+ hematopoietic stem cells (eHSC) that did not express ELANE and thus escape from the unfolded protein response (UPR) caused by mutated NE. In CyN, the CD49f+ cells respond to G-CSF with
-
Small myeloid subclones are present at diagnosis of multiple myeloma in patients who develop secondary myelodysplastic syndromes. Haematologica (IF 10.1) Pub Date : 2023-10-19 Guillaume Escure, Elise Fournier, Cynthia Saade, Lama Hasan Bou Issa, Inès Arib, Rémi Tilmont, Nicolas Gazeau, Binta M Thiam, Morgane Chovet, Maxime Delforge, Nicolas Gower, Léa Fléchon, Doriane Cavalieri, Paul Chauvet, Morgane Nudel, Laure Goursaud, Céline Berthon, Bruno Quesnel, Thierry Facon, Claude Preudhomme, Nicolas Duployez, Salomon Manier
Not available.
-
Regulatory mechanisms and context-dependent roles of TAL1 in T-cell acute lymphoblastic leukemia. Haematologica (IF 10.1) Pub Date : 2023-10-19 Jolynn Zu Lin Ong, Tze King Tan, Lu Wang, Shi Hao Tan, Takaomi Sanda
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignancy derived from thymic T-cell precursors. Approximately 40-60% of T-ALL cases exhibit aberrant overexpression of the TAL1 oncogenic transcription factor. Here, we provide a comprehensive view of the TAL1-induced transcriptional program in human T-ALL cells using a rapid protein degradation system coupled with integrative approaches
-
MYC overexpression: adding another piece to the puzzle of high-risk mantle cell lymphoma. Haematologica (IF 10.1) Pub Date : 2023-10-19 Anita Kumar
Not available.
-
Compliance and clinical benefit of deferasirox granule and dispersible tablet formulation in pediatric patients with transfusional iron overload: in a randomized, open-label, multicenter, phase II study. Haematologica (IF 10.1) Pub Date : 2023-10-19 Ali T Taher, Yasser Wali, Maria Cecilia Cruz, Pimlak Charoenkwan, Yesim Aydinok, Olena Werner, Sameera Govindaraju, Fabian Romen, Vip Viprakasit
CALYPSO (NCT02435212), a randomized, open-label, multicenter, phase 2 study evaluated the compliance, clinical benefits, and safety of deferasirox granules and dispersible tablets in pediatric patients with iron overload. Iron chelation therapy-naive and iron chelation therapy-pre-treated patients aged 2 to 0.5 mg/mg; 24.5% and 34.2%), upper respiratory tract infection (28.2% and 29.7%), and pyrexia
-
Targeting TFH cells is a novel approach for donor-specific antibody desensitization of allograft candidates: an in vitro and in vivo study. Haematologica (IF 10.1) Pub Date : 2023-10-12 Ning Ma, Wei-Bing Wu, Xiang-Yu Zhao, Lan-Ping Xu, Xiao-Hui Zhang, Yu Wang, Xiao-Dong Mo, Yuan-Yuan Zhang, Xiao-Su Zhao, Yu-Qian Sun, Yi-Fei Cheng, Kai-Yan Liu, Ying-Jun Chang, Xiao-Jun Huang
The presence of donor-specific antibodies (DSAs) are associated with graft failure either following HLA-mismatched allogeneic stem cell transplantation or after organ transplantation. Although targeting B cells and plasma cells have been used for desensitization, there have been reports of failure. T follicular helper (Tfh) cells assist B cells in differentiating into antibody-secreting plasma cells
-
Unveiling amphiregulin: a blood-based biomarker for graft-versus-host disease risk assessment and monitoring. Haematologica (IF 10.1) Pub Date : 2023-10-12 Sung Won Choi
Not available.
-
Tissue factor pathway inhibitor is associated with risk of venous thromboembolism and all-cause mortality in patients with cancer. Haematologica (IF 10.1) Pub Date : 2023-10-12 Cornelia Englisch, Florian Moik, Johannes Thaler, Silvia Koder, Nigel Mackman, Matthias Preusser, Ingrid Pabinger, Cihan Ay
Venous thromboembolism (VTE) is a common complication in patients with cancer. Data on the role of natural inhibitors of coagulation for occurrence of cancerassociated VTE are limited, thus, we investigated the association of tissue factor pathway inhibitor (TFPI) with risk of VTE and all-cause mortality in patients with cancer. Total TFPI antigen levels were measured with a commercially available
-
Eligibility criteria: too big, too small or just right? Haematologica (IF 10.1) Pub Date : 2023-10-12 Ehab Atallah
Not available.
-
Using machine learning to unravel the intricacy of acute myeloid leukemia. Haematologica (IF 10.1) Pub Date : 2023-10-12 Luca Guarnera, Valeria Visconte
Not available.
-
The splendor and the tyranny of JAK inhibition. Haematologica (IF 10.1) Pub Date : 2023-10-12 Elizabeth O Hexner
Not available.
-
Susceptibility of pediatric acute lymphoblastic leukemia to STAT3 inhibition depends on p53 induction. Haematologica (IF 10.1) Pub Date : 2023-10-05 Luca Gasparoli, Clemence Virely, Alexia Tsakaneli, Noelia Che, Darren Edwards, Jack Bartram, Michael Hubank, Deepali Pal, Olaf Heidenreich, Joost H A Martens, Jasper De Boer, Owen Williams
Advances in the clinical management of pediatric B cell Acute Lymphoblastic Leukemia (B-ALL) have dramatically improved outcomes for this disease. However, relapsed and high-risk disease still contribute to significant numbers of treatment failures. Development of new, broad range therapies is urgently needed for these cases. We previously reported the susceptibility of ETV6-RUNX1+ pediatric B-ALL
-
More than a Lonca-shot: beating the odds in relapsed/refractory diffuse large B-cell lymphoma. Haematologica (IF 10.1) Pub Date : 2023-10-05 Carrie Ho, Stephen D Smith
Not available.
-
Tucidinostat restores CCR4 expression in adult T-cell leukemia/lymphoma. Haematologica (IF 10.1) Pub Date : 2023-10-05 Takahito Kawata, Takuya Shimizu, Takero Shindo, Kensuke Fujiwara, Suguru Morimoto, Mitsumasa Watanabe
Not available.
-
Association of NUDT15 gene polymorphism with adverse reaction, treatment efficacy, and dose of 6-mercaptopurine in patients with acute lymphoblastic leukemia: a systematic review and meta-analysis. Haematologica (IF 10.1) Pub Date : 2023-10-05 Shan Du, Xuefei Huang, Xia He, Mian Mao, Min Chen, Rong Zhang, Huikai Shao, Ziyan Lv, Xinxia Liu, Junlan Chuan
6-mercaptopurine (6-MP) serves as the backbone in the maintenance regimens of acute lymphoblastic leukemia (ALL). We aimed to evaluate the influence of NUDT15 gene polymorphism on the risk of myelosuppression, hepatotoxicity and interruption of 6-MP, as well as treatment efficacy and dose of 6-MP in ALL patients. A total of 24 studies with 3374 patients were included in this meta-analysis. We found
-
Single cell analysis of the CD8+ T-cell compartment in multiple myeloma reveals disease specific changes are chiefly restricted to a CD69- subset suggesting potent cytotoxic effectors exist within the tumor bed. Haematologica (IF 10.1) Pub Date : 2023-10-05 James Favaloro, Christian E Bryant, Edward Abadir, Samuel Gardiner, Shihong Yang, Tracy King, Najah Nassif, Lisa M Sedger, Richard Boyle, Douglas E Joshua, P Joy Ho
Multiple Myeloma (MM) is an incurable disease of the bone marrow (BM) characterized by the uncontrolled proliferation of neoplastic plasma cells. While CD8+ T-cells have an established role in disease control, few studies have focused on these cells within the MM tumor microenvironment (TME). We analyzed CD8+ T-cells in the BM and peripheral blood (PB) of untreated patients with MM and non-myeloma
-
Brentuximab vedotin with chemotherapy in adolescents and young adults with stage III or IV classical Hodgkin lymphoma in ECHELON-1. Haematologica (IF 10.1) Pub Date : 2023-10-05 Howland E Crosswell, Ann S LaCasce, Nancy L Bartlett, David J Straus, Kerry J Savage, Pier Luigi Zinzani, Graham P Collins, Michelle Fanale, Keenan Fenton, Cassie Dong, Harry Miao, Andrew P Grigg
Not available.
-
Outcome of combined modality treatment in first-line for stage I(E) peripheral T-cell lymphoma; a nationwide population-based cohort study from the Netherlands. Haematologica (IF 10.1) Pub Date : 2023-10-05 Frederik O Meeuwes, Mirian Brink, Wouter Plattel, Marjolein W M Van der Poel, Marie José Kersten, Mariëlle Wondergem, Lara Böhmer, F J Sherida H Woei-A-Jin, Otto Visser, Rimke Oostvogels, Patty M Jansen, Karen J Neelis, Anne P G Crijns, Laurien A Daniëls, Tjeerd J F Snijders, Joost S P Vermaat, Gerwin A Huls, Marcel Nijland
Peripheral T-cell lymphomas (PTCL) comprise a heterogeneous group of mature T-cell neoplasms with an unfavorable prognosis; presentation with stage I(E) disease is uncommon. In clinical practice, an abbreviated chemotherapy treatment regimen combined with radiotherapy (combined modality treatment (CMT)) is commonly used, although evidence from clinical trials is lacking. The aim of this nationwide
-
Stressing the stem cell in acute myeloid leukemia. Haematologica (IF 10.1) Pub Date : 2023-10-05 Gautam Borthakur
Not available.
-
A patient with minimal myeloma treatment who survived for 20 years. Haematologica (IF 10.1) Pub Date : 2023-10-05 Alenka Djarmila Behsen, Esten Nymoen Vandsemb, Tobias Schmidt Slørdahl, Henrik Hjorth-Hansen, Petter Quist-Paulsen, Kristine Misund, Anne-Marit Sponaas, Anders Waage
Not available.
-
BH3 mimetics in relapsed and refractory adult acute lymphoblastic leukemia: a Campus ALL real-life study. Haematologica (IF 10.1) Pub Date : 2023-10-05 Francesco Malfona, Ilaria Tanasi, Matteo Piccini, Cristina Papayannidis, Vincenzo Federico, Valentina Mancini, Elisa Roncoroni, Elisabetta Todisco, Simona Bianchi, Giulia Ciotti, Patrizia Chiusolo, Massimo Gentile, Valentina Gianfelici, Fabio Giglio, Michele Malagola, Antonino Mulé, Francesco Saraceni, Calogero Vetro, Francesco Zallio, Luca Vincenzo Cappelli, Giovanni Pizzolo, Robin Foà, Massimiliano
Not available.
-
Venetoclax salvage therapy in relapsed/refractory multiple myeloma. Haematologica (IF 10.1) Pub Date : 2023-10-05 Maximilian J Steinhardt, Marietta Truger, Max Bittrich, Xiang Zhou, Julia Noderer, Christine Riedhammer, Xianghui Xiao, Sophia Gawlas, Philipp Weis, Florian Eisele, Claudia Haferlach, Julia Mersi, Johannes Waldschmidt, Hermann Einsele, Leo Rasche, K Martin Kortüm
Not available.
-
The French-American-British classification of myelodysplastic syndromes. Haematologica (IF 10.1) Pub Date : 2023-10-01 Moshe Mittelman
-
Ferroportin inhibitor vamifeport ameliorates ineffective erythropoiesis in a mouse model of β-thalassemia with blood transfusions. Haematologica (IF 10.1) Pub Date : 2023-10-01 Natarajaswamy Kalleda,Anna Flace,Patrick Altermatt,Giada Ingoglia,Cédric Doucerain,Naja Nyffenegger,Franz Dürrenberger,Vania Manolova
β-thalassemia is an inherited anemia characterized by ineffective erythropoiesis. Blood transfusions are required for survival in transfusion-dependent β-thalassemia and are also occasionally needed in patients with non-transfusion-dependent β-thalassemia. Patients with transfusion-dependent b-thalassemia often have elevated transferrin saturation (TSAT) and non-transferrin-bound iron (NTBI) levels
-
Aging-induced pseudouridine synthase 10 impairs hematopoietic stem cells. Haematologica (IF 10.1) Pub Date : 2023-10-01 Yuqian Wang,Zhenzhen Zhang,Hanqing He,Jinghui Song,Yang Cui,Yunan Chen,Yuan Zhuang,Xiaoting Zhang,Mo Li,Xinxiang Zhang,Michael Q Zhang,Minglei Shi,Chengqi Yi,Jianwei Wang
Aged hematopoietic stem cells (HSC) exhibit compromised reconstitution capacity and differentiation-bias towards myeloid lineage, however, the molecular mechanism behind it remains not fully understood. In this study, we observed that the expression of pseudouridine (Ψ) synthase 10 is increased in aged hematopoietic stem and progenitor cells (HSPC) and enforced protein of Ψ synthase 10 (PUS10) recapitulates
-
Safety and efficacy of zinpentraxin alfa as monotherapy or in combination with ruxolitinib in myelofibrosis: stage I of a phase II trial. Haematologica (IF 10.1) Pub Date : 2023-10-01 Srdan Verstovsek,Lynda Foltz,Vikas Gupta,Robert Hasserjian,Taghi Manshouri,John Mascarenhas,Ruben Mesa,Olga Pozdnyakova,Ellen Ritchie,Ivo Veletic,Katia Gamel,Habib Hamidi,Lyrialle Han,Brian Higgins,Kerstin Trunzer,Marianne Uguen,Dao Wang,Tarec Christoffer El-Galaly,Boyan Todorov,Jason Gotlib
Pentraxin 2 (PTX-2; serum amyloid P component), a circulating endogenous regulator of the inflammatory response to tissue injury and fibrosis, is reduced in patients with myelofibrosis (MF). Zinpentraxin alfa (RO7490677, PRM-151) is a recombinant form of PTX-2 that has shown preclinical antifibrotic activity and no dose-limiting toxicities in phase I trials. We report results from stage 1 of a phase
-
KIR3DL2 may represent a novel therapeutic target in aggressive systemic peripheral T-cell lymphoma. Haematologica (IF 10.1) Pub Date : 2023-10-01 Amandine Decroos,Morgane Cheminant,Julie Bruneau,Sylvain Carras,Vincent Parinet,Laura Pelletier,Laetitia Lacroix,Nadine Martin,Jérôme Giustiniani,Ludovic Lhermitte,Vahid Asnafi,Maxime Battistella,François Lemonnier,Laurence De Leval,Hélène Sicard,Cécile Bonnafous,Laurent Gauthier,Laurent Genestier,Stefano Caruso,Philippe Gaulard,Olivier Hermine,Nicolas Ortonne
-
Back to the future: the amazing journey of the therapeutic anti-leukemia enzyme asparaginase Erwinia chrysanthemi. Haematologica (IF 10.1) Pub Date : 2023-10-01 Wing H Tong,Carmelo Rizzari
For several decades, asparaginase has been considered world-wide as an essential component of combination chemotherapy for the treatment of childhood acute lymphoblastic leukemia (ALL). Discovered over 60 years ago, two main unmanipulated asparaginase products originated from primary bacteria sources, namely Escherichia coli and Erwinia chrysanthemi, have been available for clinical use. A pegylated
-
Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study. Haematologica (IF 10.1) Pub Date : 2023-09-28 Christopher R Flowers, Matthew J Matasar, Alex F Herrera, Mark Hertzberg, Sarit Assouline, Judit Demeter, Andrew McMillan, Amitkumar Mehta, Stephen Opat, Marek Trnňný, Lisa Musick, Jamie Hirata, Annie Yang, Laurie H Sehn
Follicular lymphoma (FL) is the most common type of indolent non-Hodgkin lymphoma. Despite treatment advances that have improved outcomes for patients with relapsed or refractory (R/R) FL, many patients still die from progressive disease or treatment-related toxicities. In the phase Ib/II GO29365 study (NCT02257567), the safety and efficacy of polatuzumab vedotin plus bendamustine and rituximab (Pola-BR)
-
Engineering a humanized animal model of polycythemia vera with minimal JAK2V617Fmutant allelic burden. Haematologica (IF 10.1) Pub Date : 2023-09-28 Tyler M Parsons, Aishwarya Krishnan, Wangisa M B Dunuwille, Andrew L Young, Jason Arand, Wentao Han, Grant A Challen
Not available.
-
HLA-C*04:09N is expressed at the cell surface and triggers peptide-specific T-cell activation. Haematologica (IF 10.1) Pub Date : 2023-09-28 Carlotta Welters, Marthe-Lina Welters, Serena Stadler, Lars Bullinger, Julian Strobel, Holger Hackstein, Arunraj Dhamodaran, Thomas Blankenstein, Leo Hansmann
The null allele HLA-C*04:09N differs from HLA-C*04:01 in a frameshift mutation within its cytoplasmic domain, resulting in translation of 32 additional amino acids that are assumed to prevent cell surface expression. However, we recently identified a multiple myeloma-reactive T-cell receptor (TCR) that appeared to recognize antigen presented on HLA-C*04:09N and encouraged us to ask whether HLA-C*04:09N
-
Circulating tumor DNA and bone marrow minimal residual disease negativity confers superior outcome for multiple myeloma patients. Haematologica (IF 10.1) Pub Date : 2023-09-28 Sridurga Mithraprabhu, John Reynolds, Hang Quach, Noemi Horvath, Ian Kerridge, Tiffany Khong, Brian Gm Durie, Andrew Spencer
Not available.
-
Profiling the activity of the para-caspase MALT1 in B-cell acute lymphoblastic leukemia for potential targeted therapeutic application. Haematologica (IF 10.1) Pub Date : 2023-09-28 Firas M Safa, Terri Rasmussen, Lorena Fontan, Min Xia, Ari Melnick, Adrian Wiestner, Patricia Lobelle-Rich, Jan A Burger, Yara Mouawad, Hana Safah, Erik K Flemington, Nakhle S Saba
B cell acute lymphoblastic leukemia (B-ALL) remains a hard-to-treat disease with a poor prognosis in adults. Mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) is a para-caspase required for B-cell receptor (BCR)-mediated NF-κB activation. Inhibition of MALT1 in preclinical models has proven efficacious in many B-cell malignancies including chronic lymphocytic leukemia, mantle
-
Regulatory T cells hamper the efficacy of T-cell engaging bispecific antibody therapy. Haematologica (IF 10.1) Pub Date : 2023-09-28 Mika Casey, Carol Lee, Wing Yu Kwok, Soi Cheng Law, Dillon Corvino, Maher K Gandhi, Simon J Harrison, Kyohei Nakamura
T cell-engaging bispecific antibodies (T-BsAbs) have shown impressive clinical responses in patients with relapsed/refractory B-cell malignancies, although treatment failure remains a major clinical challenge. Growing evidence suggests that the complex interplay between immune cells and tumor cells is implicated in the mechanism of action, and thus, understanding immune regulatory mechanisms might
-
Lower overall survival in male patients with advanced disease undergoing allogeneic hematopoietic stem cell transplantation is associated with CYP1B1 Leu432Val polymorphism. Haematologica (IF 10.1) Pub Date : 2023-09-28 Norbert Stute, Michael Koldehoff
Human cytochrome P450 1B1 (CYP1B1) is an extrahepatic key enzyme involved in estrogen metabolism, steroid synthesis, and pro-carcinogen activation. In a single-center retrospective study, 382 patients who underwent allogeneic HSCT and their donors were genotyped for CYP1B1 (C432G) polymorphism by rt-PCR. 169 patients (44%) were homozygous wild-type (wt) gene CC, 157 (41%) heterozygous CG and 56 (15%)
-
Ribosomal protein S3 mediates drug resistance of proteasome inhibitor: potential therapeutic application in multiple myeloma. Haematologica (IF 10.1) Pub Date : 2023-09-28 Gege Chen, Xuejie Gao, Xinyan Jia, Yingcong Wang, Li Xu, Dandan Yu, Shuaikang Chang, Hui Deng, Ke Hu, Guanli Wang, Bo Li, Zhijian Xu, Yumeng Lu, Huaping Wang, Ting Zhang, Dongliang Song, Guang Yang, Xiaosong Wu, Huabin Zhu, Weiliang Zhu, Jumei Shi
Multiple myeloma (MM) remains incurable due to drug resistance. Ribosomal protein S3 (RPS3) has been identified as a non-Rel subunit of NF-κB. However, the detailed biological roles of RPS3 remain unclear. Here, we report for the first time that RPS3 is necessary for MM survival and drug resistance. RPS3 was highly expressed in MM, and knockout of RPS3 in MM inhibited cell growth and induced cell apoptosis
-
Concurrent peripheral T-cell lymphoma and T-cell lymphoblastic leukemia/lymphoma with identical STIL::TAL1 fusion events. Haematologica (IF 10.1) Pub Date : 2023-09-28 Mahsa Khanlari, Wei Wang, Yen-Chun Liu, Lu Wang, Jeffrey E Rubnitz, Stephanie Dixon, Brent A Orr, Obianuju M Anelo, Zhongshan Cheng, Vidya Balagopal, Jeffery M Klco
Not available.
-
Twist family BHLH transcription factor 1 is required for the maintenance of leukemia stem cell in MLL-AF9+ acute myeloid leukemia. Haematologica (IF 10.1) Pub Date : 2023-09-28 Nan Wang, Jing Yin, Na You, Wenqi Zhu, Nini Guo, Xiaoyan Liu, Peiwen Zhang, Wanling Huang, Yueqiao Xie, Qian Ren, Xiaotong Ma
Leukemia stem cells (LSCs) are a rare population capable of limitless self-renewal and are responsible for the initiation, maintenance, and relapse of leukemia. Elucidation of the mechanisms underlying the regulation of LSC function could provide novel treatment strategies. Here, we show that TWIST1 is extremely highly expressed in the LSCs of MLL-AF9+ acute myeloid leukemia (AML), and its upregulation